These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 14709627)
1. Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Stresser DM; Broudy MI; Ho T; Cargill CE; Blanchard AP; Sharma R; Dandeneau AA; Goodwin JJ; Turner SD; Erve JC; Patten CJ; Dehal SS; Crespi CL Drug Metab Dispos; 2004 Jan; 32(1):105-12. PubMed ID: 14709627 [TBL] [Abstract][Full Text] [Related]
2. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187 [TBL] [Abstract][Full Text] [Related]
3. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Chang SY; Chen C; Yang Z; Rodrigues AD Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Grimm SW; Dyroff MC Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599 [TBL] [Abstract][Full Text] [Related]
5. Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes. Chanteux H; Rosa M; Delatour C; Nicolaï J; Gillent E; Dell'Aiera S; Ungell AL Drug Metab Dispos; 2020 Sep; 48(9):778-787. PubMed ID: 32532738 [TBL] [Abstract][Full Text] [Related]
6. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4. Renwick AB; Lewis DF; Fulford S; Surry D; Williams B; Worboys PD; Cai X; Wang RW; Price RJ; Lake BG; Evans DC Xenobiotica; 2001 Apr; 31(4):187-204. PubMed ID: 11465405 [TBL] [Abstract][Full Text] [Related]
7. The xenobiotic inhibitor profile of cytochrome P4502C8. Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296 [TBL] [Abstract][Full Text] [Related]
8. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Ghosal A; Ramanathan R; Yuan Y; Hapangama N; Chowdhury SK; Kishnani NS; Alton KB Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338 [TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Bourrié M; Meunier V; Berger Y; Fabre G J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937 [TBL] [Abstract][Full Text] [Related]
10. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Bourrié M; Meunier V; Berger Y; Fabre G Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518 [TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523 [TBL] [Abstract][Full Text] [Related]
12. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Ma B; Prueksaritanont T; Lin JH Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Lillibridge JH; Liang BH; Kerr BM; Webber S; Quart B; Shetty BV; Lee CA Drug Metab Dispos; 1998 Jul; 26(7):609-16. PubMed ID: 9660842 [TBL] [Abstract][Full Text] [Related]
14. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228 [TBL] [Abstract][Full Text] [Related]
15. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Narimatsu S; Yonemoto R; Saito K; Takaya K; Kumamoto T; Ishikawa T; Asanuma M; Funada M; Kiryu K; Naito S; Yoshida Y; Yamamoto S; Hanioka N Biochem Pharmacol; 2006 Apr; 71(9):1377-85. PubMed ID: 16510126 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5. Li X; Song X; Kamenecka TM; Cameron MD Drug Metab Dispos; 2012 Sep; 40(9):1803-9. PubMed ID: 22696420 [TBL] [Abstract][Full Text] [Related]
17. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Guo Z; Raeissi S; White RB; Stevens JC Drug Metab Dispos; 1997 Mar; 25(3):390-3. PubMed ID: 9172960 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate. Kim JY; Baek M; Lee S; Kim SO; Dong MS; Kim BR; Kim DH Drug Metab Dispos; 2001 Dec; 29(12):1555-60. PubMed ID: 11717174 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro. Iwase M; Kurata N; Ehana R; Nishimura Y; Masamoto T; Yasuhara H Hum Exp Toxicol; 2006 Dec; 25(12):715-21. PubMed ID: 17286149 [TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]